Melbourne International Joint Breast Congress

Australasian Society for Breast Disease (ASBD)
4th World Congress on Controversies in Breast Cancer (CoBrCa)
Breast Surgeons of Australia & New Zealand (BreastSurgANZ)

CONGRESS PROGRAM

Melbourne, Australia
October 11-13, 2018

www.melbournebreast2018.org
# Timetable

## Thursday, October 11, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall A</th>
<th>Hall B</th>
<th>Hall C</th>
<th>Hall D</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-12:20</td>
<td>Pre-Congress Workshop 1: From concept to publication: Clinical trials</td>
<td>Pre-Congress Workshop 2: Pathology - shades of grey: When the answer is</td>
<td>Pre-Congress Workshop 3: The challenging patient</td>
<td></td>
</tr>
<tr>
<td></td>
<td>in cancer</td>
<td>non-definitive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:20-13:20</td>
<td>Lunch break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:20-16:40</td>
<td>Pre-Congress Workshop 4: Managing breast cancer in resource poor locations</td>
<td>Pre-Congress Workshop 5: Radiation oncology</td>
<td>Pre-Congress Workshop 6: The tortuous road to diagnosis</td>
<td></td>
</tr>
<tr>
<td>16:40-17:15</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:15-17:30</td>
<td>Congress Opening</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30-19:00</td>
<td>Plenary Session 1: Neoadjuvant therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Friday, October 12, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall A</th>
<th>Hall B</th>
<th>Hall C</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00-08:30</td>
<td>Morning Industry Symposium: Practice changing new perspectives on</td>
<td>Morning Industry Symposium: CDK4/6 inhibitors in advanced breast cancer:</td>
<td>Parallel Session 4: Free Papers: Medical oncology</td>
</tr>
<tr>
<td></td>
<td>genomic profiling in the management of ER+, HER2+ Early Breast Cancer</td>
<td>The future is now supported by Pfizer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Supported by Genomic Health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30-09:30</td>
<td>Parallel Session 2: Screening</td>
<td>Parallel Session 3: Keeping patients on their endocrine treatments</td>
<td></td>
</tr>
<tr>
<td>09:30-11:00</td>
<td>Plenary Session 5: Genetics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Coffee break and poster viewing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30-12:30</td>
<td>Parallel Session 6: Imaging</td>
<td>Parallel Session 7: Free Papers: Surgery/Radiotherapy</td>
<td></td>
</tr>
<tr>
<td>12:30-13:30</td>
<td>Coffee break and poster viewing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30-14:30</td>
<td>Parallel Session 8: Controversies in reconstruction</td>
<td>Industry Symposium: New paradigms in the treatment of HER2+ early breast</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cancer supported by Roche</td>
<td></td>
</tr>
<tr>
<td>14:30-15:50</td>
<td>Plenary Session 9: Adjuvant endocrine therapy</td>
<td>Parallel Session 8: Free Papers: Medical oncology</td>
<td></td>
</tr>
<tr>
<td>15:50-16:10</td>
<td>Parallel Session 10: Molecular assays</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:10-17:30</td>
<td>Life after breast cancer</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Saturday, October 13, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall A</th>
<th>Hall B</th>
<th>Hall C</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00-08:30</td>
<td>Morning Industry Symposium: Old favourites, new strategies: Chemotherapy</td>
<td>Morning Industry Symposium: Attractive techniques for localisation and</td>
<td>10:30-13:00</td>
</tr>
<tr>
<td></td>
<td>and the treatment of MBC supported by Eisai</td>
<td>staging: Tools for everyone supported by Magseed</td>
<td>Breast Cancer Network Australia</td>
</tr>
<tr>
<td>08:30-09:30</td>
<td>Parallel Session 12: DCE</td>
<td>Parallel Session 13: Topics in chemotherapy</td>
<td></td>
</tr>
<tr>
<td>09:30-11:00</td>
<td>Plenary Session 15: Loco-Regional therapy</td>
<td>Parallel Session 14: Free Papers: Screening/Treatment effects/</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Supportive care</td>
<td></td>
</tr>
<tr>
<td>11:00-11:30</td>
<td>Coffee break and poster viewing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30-13:00</td>
<td>Parallel Session 16: Local therapy</td>
<td>Industry Symposium: Key issues around bone health supported by Amgen</td>
<td></td>
</tr>
<tr>
<td>13:00-14:00</td>
<td>Lunch break and poster viewing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00-15:00</td>
<td>Parallel Session 17: Exercise and lymphoedema</td>
<td>Parallel Session 18: CNS metastases</td>
<td></td>
</tr>
<tr>
<td>15:00-16:15</td>
<td>Plenary Session 20: Breast Cancer 2025</td>
<td>Parallel Session 19: Breast surgery</td>
<td></td>
</tr>
<tr>
<td>16:15-16:30</td>
<td>Congress closing and Award presentation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Dear Friends and Colleagues,

We are pleased to welcome you to the Melbourne International Joint Breast Congress (MIBC), held jointly with the Australasian Society for Breast Disease (ASBD), 4th World Congress on Controversies in Breast Cancer (CoBrCa) and Breast Surgeons of Australia and New Zealand (BreastSurgANZ).

The Joint Congress combines the traditional features of the conferences of all three organisations - a wide multidisciplinary program, in depth analysis of various aspects of breast surgical practice, and an approach of directly addressing key issues facing clinicians in their daily practice. We believe that the collaboration has created a multi-faceted congress of interest to all involved in the treatment of breast disease.

We are delighted to have assembled a stellar international and national faculty, and thank all of those who have agreed to participate and those who have submitted abstracts.

We would like to thank the supporters, without whose backing this congress could not take place, as well as all of you who have travelled from across the city or the world to attend the congress.

We look forward to your participation in the sessions and trust that it is an informative and enjoyable experience.

Enjoy your time in the exciting and modern city of Melbourne.

Sincerely,
Congress Chairpersons

Yvonne Zissiadis, Australia
Australasian Society for Breast Disease (ASBD)

Bruce Mann, Australia
4th World Congress on Controversies in Breast Cancer (CoBrCa)

Christobel Saunders, Australia
Breast Surgeons of Australia and New Zealand (BreastSurgANZ)
CPD ACCREDITATION

Royal Australasian College of Physicians (RACP)
Fellows of the Royal Australasian College of Physicians (RACP) should individually claim CPD credits in the online MyCPD program, based on the number of hours they have attended. The MyCPD program is a self-directed and self-reporting tool enabling participants to record and report on CPD activities they judge relevant to the scope of their practice.

Fellows can claim 1 credit per hour of attendance at the MIBC congress in the MyCPD program.

Royal Australasian College of General Practitioners (RACGP)
Fellows of the Royal Australasian College of General Practitioners (RACGP) may claim QI&CPD points by self-recording online at the RACGP website www.racgp.org.au and supplying a certificate of attendance with the program outline.

The Royal Australian and New Zealand College of Radiologists (RANZCR)
A total of 20.25 RANZCR CPD points can be claimed for attendance at the Melbourne International Joint Breast Congress (MIBC).
4.75 points may be claimed for attendance on 11/10/2018.
8 points may be claimed for attendance on 12/10/2018.
7.5 points may be claimed for attendance on 13/10/2018.
For anyone who attends only part of a session, points may be claimed pro rata at 1 point per hour per lecture.

Royal Australasian College of Surgeons
This educational activity has been approved in the RACS CPD Program. Fellows who participate can claim one point per hour in Maintenance of Knowledge and Skills.

Participation in this activity will be populated into your RACS CPD Online.

MIBC at Your Fingertips
Download the app and gain access to everything you need to know to plan a successful event.

MIBC is proud to introduce the Congress APPLICATION – a state-of-the-art educational tool dedicated to implementing innovative and environmentally-friendly technology. The MIBC App is your best tool for planning and organizing your participation and keeping up to date.

The App can be downloaded via your personal device through both Google Play and Apple stores. In order to access the MIBC congress program, abstracts and other information, please scan the relevant QR code or click on the relevant short link below:

All Devices
(with this you are able to choose between android or ios once you click on the link or scan the QR code)
Short link: http://bit.ly/2qtzulg

iPhone
Short link: http://bit.ly/2qtxVb

Android
Short link: http://bit.ly/2qtyB8S
Thursday, October 11, 2018

09:00-12:20  Pre-Congress Workshop 1: From concept to publication: Clinical trials in cancer

Chairperson: Arlene Chan, Australia

Speakers:
- Arlene Chan, Australia - Medical oncology
- Boon Chua, Australia - Radiation oncology
- Andrew Spillane, Australia - Breast surgery

09:00-09:10  Opening: Goals and benefits of clinical research
Arlene Chan, Australia

09:10-09:40  Goals of workshop: Spectrum of research, GCP/NHMRC, trial conduct, protocol basics
Arlene Chan, Australia

Questions from the audience

09:45-10:00  Phases of clinical trials, protocol development
Arlene Chan, Australia

Regulatory, ethics and governance
Arlene Chan, Australia

10:00-10:30  Group activity

10:30-10:50  Coffee Break

10:50-11:20  Group presentation and discussion

11:20-11:40  Scope and pitfalls of surgical research
Andrew Spillane, Australia

11:40-12:00  Scope and pitfalls of radiation oncology research
Boon Chua, Australia

12:00-12:15  How to present at a clinical meeting
Arlene Chan, Australia

12:15-12:20  Roundup
09:00-12:20  Pre-Congress Workshop 2:
Pathology – shades of grey: When the answer is non-definitive

Chairperson:  Nirmala Pathmanathan, Australia

09:00-09:30 Spindle cell lesions of the breast and their significance
Stephen Fox, Australia

09:30-10:00 The spectrum of lesions from atypia to DCIS and lobular neoplasia, significance and management
Sunil Lakhani, Australia

10:00-10:30 Radial scars, papillomas and other benign proliferative lesions, significance and management
Gelareh Farshid, Australia

10:30-10:50 Coffee Break

10:50-11:20 ER, PR and HER2 testing controversies and the classification of breast cancer
David Clouston, Australia

11:20-12:10 Breast cancer prognosis: Is grade still relevant?
Nirmala Pathmanathan, Australia

12:10-12:20 Panel discussion

09:00-12:20  Pre-Congress Workshop 3:
The challenging patient

Chairperson:  Norman Swan, Australia

09:00-09:15 Who are the challenging patients and how do they challenge us?
Christobel Saunders, Australia

09:15-09:35 Can we understand their challenges?
Jane Turner, Australia

09:35-09:55 What are our legal obligations?
Ian Freckelton, Australia

09:55-10:15 The US experience
Reshma Jagsi, USA

10:15-10:30 Managing challenging patients, clinician-patient encounters
Lesley Stafford, Australia

10:30-10:50 Coffee Break

10:50-12:20 Panel and audience discussion
Christobel Saunders, Australia; Ian Freckelton, Australia; Reshma Jagsi, USA; Lesley Stafford, Australia; Fran Boyle, Australia; Jane Turner, Australia; Alexis Butler, Australia; Kerry Shanahan, Australia; Danielle Spence, Australia

12:20-13:20 Lunch Break
13:20-16:40  Pre-Congress Workshop 4: Managing breast cancer in resource poor locations

Chairperson: Jacinta Elston, Australia

13:20-13:30  Introduction
Jacinta Elston, Australia

13:30-14:00  East Timor - setting up a breast service in one of the world's most resource poor nations
Alito Soares, Timor Leste
Danielle Spence, Australia
Christobel Saunders, Australia

14:00-14:20  Developing breast cancer services and advocacy in India
Raghu Ram, India

14:20-14:40  How to get radiotherapy to resource-poor nations
Mei Ling Yap, Australia

14:40-15:00  Coffee Break

15:00-15:20  Breast cancer in Maori and Pasifika
Ian Campbell, New Zealand

15:20-15:50  Breast cancer in Indigenous Australia
Jacinta Elston, Australia
Jennifer Chynoweth, Australia

15:50-16:40  Panel discussion:
Jacinta Elston, Australia; Alito Soares, Timor Leste; Danielle Spence, Australia; Christobel Saunders, Australia; Raghu Ram, India; Mei-Ling Yap, Australia; Ian Campbell, New Zealand; Jennifer Chynoweth, Australia; Josese Turageva, Fiji

13:20-16:40  Pre-Congress Workshop 5: Radiation oncology

Chairpersons: Minjae Lah, Australia
Yvonne Zissiadis, Australia

13:20-13:25  Welcome and introduction of speakers
Minjae Lah, Australia
Yvonne Zissiadis, Australia

13:25-13:45  Post-mastectomy RT in node negative and N1 patients
Reshma Jagsi, USA

13:45-14:05  Discussion

14:05-14:25  Cardiotoxicity: When do we start to worry?
Lori Pierce, USA

14:25-14:50  Discussion

14:50-15:10  Coffee Break

15:10-15:30  Integrating RT and breast reconstruction
Reshma Jagsi, USA

15:30-15:45  Discussion

15:45-16:00  Cardio-oncology programs: Part of our quality control?
Lori Pierce, USA

16:00-16:20  Q & A
13:20-16:40  Pre-Congress Workshop 6: The tortuous road to diagnosis  
**Chairperson:**  Jill Evans, Australia

13:20-13:40  When is a lump a lump?  
**Jennifer O’Sullivan,** Australia

13:40-14:10  Breastscreen assessment: Not always smooth sailing  
**Nick Repin,** Australia

14:10-14:40  Imaging diagnostic conundrums  
**Liz Wylie,** Australia

14:40-15:00  Coffee Break

15:00-16:00  Surgery & Pathology:  
Uncertainties and grey areas in breast pathology: When is surgical intervention needed?  
**Nirmala Pathmanathan,** Australia  
**Elisabeth Elder,** Australia

16:00-16:40  Panel and audience discussion

17:15-17:30  Congress Opening

17:30-19:00  Plenary Session 1: Neoadjuvant therapy  
**Chairpersons:**  Richard de Boer, Australia  
Christobel Saunders, Australia

17:30-18:00  DEBATE: That decisions regarding NAST should be based on TN stage rather than breast cancer subtype  
17:30  **TN stage:** Bruce Mann, Australia  
17:40  **Breast cancer subtypes:** Stephen Johnston, UK  
17:50  Discussion

18:00-18:30  The potential of neoadjuvant endocrine therapy  
**Mitch Dowsett,** UK

18:30-19:00  DEBATE: That further chemotherapy should be recommended for patients with ER-ve cancer not achieving pCR  
18:30  **Yes:** Stacy Moulder, USA  
18:40  **No:** Nicholas Wilcken, Australia  
18:50  Discussion

19:00  Networking Reception
Friday, October 12, 2018

**07:00-08:30 Morning Industry Symposium:**
**Practice-changing new perspectives on genomic profiling in the management of HR+, HER2- Early Breast Cancer**
Supported by Genomic Health

Breakfast will be served prior to the session

For full details, please refer to page??

**07:00-08:30 Morning Industry Symposium:**
**CDK4/6 inhibitors in advanced breast cancer: The future is now**
Supported by Pfizer

Breakfast will be served prior to the session

For full details, please refer to page??

**08:30-09:30 Parallel Session 2:**
**Screening**

Chairpersons: Gelareh Farshid, Australia
Allison Rose, Australia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:05</td>
<td>DEBATE: That BreastScreen Australia requires urgent and radical reform</td>
</tr>
<tr>
<td></td>
<td><strong>Yes:</strong> Alexandra Barratt, Australia</td>
</tr>
<tr>
<td></td>
<td><strong>No:</strong> Bruce Mann, Australia</td>
</tr>
<tr>
<td>08:50</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

09:05-09:20  Mammographic density
Jack Cuzick, UK

09:20-09:30  Validation of iPrevent, an online breast cancer risk assessment and risk management decision support tool
Kelly-Anne Phillips, Australia

08:30-09:30  Parallel Session 3:
**Keeping patients on their endocrine treatments**

Chairpersons: Nicole McCarthy, Australia
Lisa Sheeran, Australia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-08:50</td>
<td>The biology of endocrine side effects</td>
</tr>
<tr>
<td></td>
<td>Mitch Dowsett, Australia</td>
</tr>
<tr>
<td>09:05-09:05</td>
<td>Below the breast: Managing genitourinary symptoms</td>
</tr>
<tr>
<td></td>
<td>Martha Hickey, Australia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:05-09:30</td>
<td>DEBATE: How to best manage endocrine therapy symptoms: Pharma or sweat?</td>
</tr>
<tr>
<td>09:05</td>
<td><strong>SWEAT:</strong> Prue Cormie, Australia</td>
</tr>
<tr>
<td>09:15</td>
<td><strong>PHARMA:</strong> Fran Boyle, Australia</td>
</tr>
<tr>
<td>09:25</td>
<td>Discussion</td>
</tr>
</tbody>
</table>
08:30-09:30 Parallel Session 4: Free Papers: Medical oncology

Chairpersons: Nick Murray, Australia
               Catherine Oakman, Australia

08:30-08:40 Neoadjuvant chemotherapy rates for breast cancer in Australia: Are we there yet?
             Paul Patiniott, Australia

08:40-08:50 Curative Intent Stereotactic Ablative Body Radiotherapy (SABR) in oligometastatic breast cancer: Final results of a Phase I clinical trial
             Steven David, Australia

08:50-09:00 Cryoablation of breast cancer in metastatic patients. Preliminary experience
             Claudio Pusceddu, Italy

09:00-09:10 Ribociclib with endocrine therapy for premenopausal women with hormone receptor positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC): Additional results from the Monaleesa-7 trial
             Louis Chow, Hong Kong

09:10-09:20 Canassist-breast: Unique immunohistochemistry based test for risk of recurrence prediction for early stage breast cancer patients: A cost-effective, accurate and broad based solution for Asia
             Manjiri Bakre, India

09:20-09:30 Phase 2 keynote-086 trial: Relationship between response to pembrolizumab and tumor infiltrating lymphocyte (TIL) levels in metastatic triple-negative breast cancer (mTNBC)
             Sherene Loi, Australia

09:30-11:00 Plenary Session 5: Genetics

Chairpersons: Geoff Lindeman, Australia
               Lara Lipton, Australia

09:30-10:00 DEBATE: That most patients with breast cancer should be panel tested for germline mutations
             09:30 Yes: Paul James, Australia
             09:40 No: Marion Harris, Australia
             09:50 Discussion

10:00-10:30 The medical implications of panel testing: Platinums/PARPi’s
             Rebecca Dent, Singapore

10:30-11:00 DEBATE: That gene carriers diagnosed with cancer should be strongly advised to undergo bilateral mastectomy
             10:30 Yes: James French, Australia
             10:40 No: Christopher Pyke, Australia
             10:50 Discussion

11:00-11:30 Coffee break and poster viewing
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairpersons</th>
<th>Details and Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30-12:30</td>
<td>Parallel Session 6:</td>
<td>Seigo Nakamura, Japan</td>
<td>Imaging</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Belinda Yeo, Australia</td>
<td></td>
</tr>
<tr>
<td>11:30-11:50</td>
<td>Assessment of response to neoadjuvant chemotherapy</td>
<td>Clair Shadbolt, Australia</td>
<td></td>
</tr>
<tr>
<td>11:50-12:10</td>
<td>New paradigms in breast imaging: The 7-8 minutes that make a difference</td>
<td>Allison Rose, Australia</td>
<td></td>
</tr>
<tr>
<td>12:10-12:30</td>
<td>PET in breast cancer</td>
<td>Kate Moodie, Australia</td>
<td></td>
</tr>
<tr>
<td>11:30-12:30</td>
<td>Industry Symposium:</td>
<td></td>
<td>Clinical controversies in HER2+ early breast cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Supported by Roche</td>
</tr>
<tr>
<td></td>
<td>For full details, please refer to page??</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30-12:30</td>
<td>Parallel Session 7:</td>
<td>Michael Chao, Australia</td>
<td>Free Papers: Surgery/Radiotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sanjay Warrier, Australia</td>
<td></td>
</tr>
<tr>
<td>11:30-11:40</td>
<td>Radioactive iodine seed localization in axilla with sentinel node biopsy (RISAS): A Dutch prospective multicenter trial on axillary staging after neoadjuvant chemotherapy in node positive breast cancer</td>
<td>Natacha Ruyssers, Belgium</td>
<td></td>
</tr>
<tr>
<td>11:40-11:50</td>
<td>Spy fluorescence angiography: An adjunct to identifying cases suitable for staged breast reconstruction</td>
<td>Nita Bartlett, Australia</td>
<td></td>
</tr>
<tr>
<td>11:50-12:00</td>
<td>Intraoperative Assessment (IOA) of the Sentinel Node (SN) in breast cancer by One Step Nucleic acid Assay (OSNA): Warwick experience of over 1100 patients</td>
<td>Dayalan Clarke, UK</td>
<td></td>
</tr>
<tr>
<td>12:00-12:10</td>
<td>Implications of the St George randomized breast boost trial for reduced volume or dose breast radiotherapy strategies</td>
<td>Peter Graham, Australia</td>
<td></td>
</tr>
<tr>
<td>12:10-12:20</td>
<td>Active monitoring is an acceptable choice for women with low risk ductal carcinoma in situ (DCIS): An assessment of quality of life</td>
<td>Hannah Bromley, Australia</td>
<td></td>
</tr>
<tr>
<td>12:20-12:30</td>
<td>The UK-ANZ NeST (neoadjuvant systemic therapy in breast cancer) multicenter collaborative study</td>
<td>Stuart McIntosh, UK</td>
<td></td>
</tr>
<tr>
<td>12:30-13:30</td>
<td>Lunch break and poster viewing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Chairpersons</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------</td>
<td>-------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 13:30-14:30| Parallel Session 8:  
Controversies in reconstruction | Elisabeth Elder, Australia    
Andrew Spillane, Australia |
| 13:30-14:00| DEBATE: That neoadjuvant RT prior to TM/reconstruction is a better approach than post-mastectomy RT | Yes: Caroline Baker, Australia  
No: Boon Chua, Australia  
Discussion |
| 14:00-14:30| DEBATE: That two-stage implant based reconstruction is rarely indicated in the setting of skin or nipple sparing mastectomy | Yes: James French, Australia  
No: Dean Trotter, Australia  
Discussion |
| 13:30-14:30| Industry Symposium:  
New paradigms in the treatment of HR+HER2- mBC: CDK4/6 inhibitors and beyond | Supported by Novartis |
| 14:30-15:50| Plenary Session 9:  
Adjuvant endocrine therapy | Stephen Johnston, UK  
Linda Vahdat, USA |
| 14:30-14:40| What is the ER/PR threshold at which endocrine therapy should be prescribed, or may be relied upon? | Yes: Yoland Antill, Australia  
No: Catherine Oakman, Australia  
Discussion |
| 14:40-15:10| DEBATE: That topical oestrogens are an acceptable treatment in pts with HR+ve early breast cancer | Yes: Yoland Antill, Australia  
No: Catherine Oakman, Australia  
Discussion |
| 15:10-15:20| Update on SOFT/TEXT | Prue Francis, Australia |
| 15:20-15:50| DEBATE: That 10 years of AET is overtreatment | Yes: Janice Tsang, Hong Kong  
No: Nicole McCarthy, Australia  
Discussion |
| 15:50-16:10| Coffee break and poster viewing |
16:10-17:30 Parallel Session 10: Molecular assays  

**Chairpersons:** Bruce Mann, Australia  
Louis Chow, Hong Kong

16:10-16:25 The case for using Oncotype DX  
**Virginia Kaklamani, USA**

16:25-16:40 The case for using Endopredict  
**Mitch Dowsett, UK**

16:40-16:55 The case for using Mammaprint  
**Alastair Thompson, USA**

16:55-17:10 The case for using Prosigna  
**Janice Tsang, Hong Kong**

17:10-17:25 The case for rarely using an assay  
**Belinda Yeo, Australia**

17:25-17:30 Discussion

16:10-17:30 Parallel Session 11: Life after breast cancer  

**Chairperson:** Lesley Stafford, Australia

16:10-16:40 Risking another cancer: Who should have a mastectomy/CPM?  
**Laura Esserman, USA**

16:40-17:00 Motivational interviewing: How to get the best lifestyle outcomes from your patients  
**Sarah Hardcastle, Australia**

17:00-17:30 Brains (cognitive decline) and breast cancer  
**Adam Walker, Australia**
Saturday, October 13, 2018

07:00-08:30 Morning Industry Symposium:
Old favourites, new strategies: Chemotherapy and the treatment of MBC
Supported by Eisai

Breakfast will be served prior to the session

For full details, please refer to page??

07:00-08:30 Morning Industry Symposium:
Attractive techniques for localisation and staging: Tools for everyone
Supported by EBOS and Magseed

Breakfast will be served prior to the session

For full details, please refer to page??

08:30-09:30 Parallel Session 12:
DCIS
Chairpersons: Christopher Pyke, Australia
                Yvonne Zissiadis, Australia

08:30-09:00 DEBATE: That RT after WE for DCIS is usually overtreatment
08:30 Yes: Laura Esserman, USA
08:40 No: Lori Pierce, USA
08:50 Discussion

09:00-09:20 Active surveillance is an option for low-risk DCIS
Christobel Saunders, Australia

09:20-09:30 Discussion

08:30-09:30 Parallel Session 13:
Topics in chemotherapy
Chairpersons: Rebecca Dent, Singapore
                Elgene Lim, Australia

08:30-09:00 DEBATE: That dose-dense chemotherapy should be the standard for all subtypes of early breast cancer
08:30 Yes: Linda Vahdat, USA
08:40 No: Richard de Boer, Australia
08:50 Discussion

09:00-09:15 New strategies in early stage TNBC
Stacy Moulder, USA

09:15-09:30 Will NGS become a standard part of management of breast cancer?
Sarah-Jane Dawson, Australia
08:30-09:30 Parallel Session 14:
Free Papers: Screening/Treatment effects/Supportive care

Chairpersons: Jocelyn Lippey, Australia
              Kerry Shanahan, Australia

08:30-08:40 Liposuction for advanced breast cancer-related lymphoedema: Outcomes of a multidisciplinary team approach
              John Boyages, Australia

08:40-08:50 Identification of breast cancer survivors’ side effects and supportive care needs
              Christina Kozul, Australia

08:50-09:00 Physical function following breast reconstructive surgery: Are musculoskeletal side-effects a problem?
              Deirdre McGhee, Australia

09:00-09:10 Patient reported experiences from the persephone early breast cancer trial
              Janet Dunn, UK

09:10-09:20 Prospective three-arm triple-blinded comparative study for breast cancer screening in low resource setting countries with a noninvasive and low-cost technique using a handheld point-of-care medical device (iBreastexam)
              S.P. Somashekhar, India

09:20-09:30 Health system barriers to the provision of breast reconstruction options in Australia: Improving informed choice through appropriate referral
              Kathy Flitcroft, Australia

09:30-11:00 Plenary Session 15:
Loco-Regional therapy

Chairpersons: Caroline Baker, Australia
              Boon Chua, Australia

09:30-10:00 DEBATE: That all patients with axillary nodal disease pre-NACT should have axillary dissection or radiation
              09:30 Yes: Yvonne Zissiadis, Australia
              09:40 No: Jane O’Brien, Australia
              09:50 Discussion

10:00-10:20 The implications of the AMAROS study
              Lori Pierce, USA

10:20-11:00 DEBATE: That regional nodal radiation is appropriate for most patients with nodal disease
              10:20 Yes: Reshma Jagsi, USA
              10:35 No: Louis Chow, Hong Kong
              10:50 Discussion

11:00-11:30 Coffee break and poster viewing
11:30-13:00 Parallel Session 16: Local therapy

Chairpersons: James French, Australia
Jane Fox, Australia

11:30-12:00 DEBATE: Margins: That “no tumour on ink” is a dangerous over-simplification
11:30 Yes: Ian Campbell, New Zealand
11:40 No: Raghu Ram, India
11:50 Discussion

12:00-12:30 The status of intra-operative techniques for localization/margin assessment
Alistair Thompson, USA

12:30-13:00 DEBATE: That IORT is ready for prime time
12:30 Yes: Dennis R. Holmes, USA
12:40 No: Michael Chao, Australia
12:50 Discussion

11:30-13:00 Industry Symposium: Key issues around bone health
Supported by Amgen

For full details, please refer to page??

10:30-13:00 Breast Cancer Network Australia: Metastatic breast cancer

13:00-14:00 Lunch break and poster viewing

14:00-15:00 Parallel Session 17: Exercise and lymphoedema

Chairpersons: Kerry Shanahan, Australia
Lisa Sheeran, Australia

14:00-14:20 Surgery for lymphoedema: A new paradigm
Ramin Shayan, Australia

14:20-14:40 Prescribing exercise and putting it into practice
Prue Cormie, Australia

14:40-15:00 Wearable technology and influencing health behaviours
Sarah Hardcastle, Australia
14:00-15:00   Parallel Session 18: CNS metastases

Chairpersons: Minjae Lah, Australia
              Stacy Moulder, USA

14:00-14:20  Molecular pathology of CNS metastases
              Sunil R. Lakhani, Australia
              Stacy Moulder, USA

14:20-14:40  Local therapy for CNS metastases: The roles of surgery, SRS and WBRT in 2018
              Claire Phillips, Australia

14:40-15:00  Drug treatment for CNS metastasis
              Arlene Chan, Australia

14:00-15:00   Parallel Session 19: Breast surgery

Chairpersons: Ian Campbell, New Zealand
              Raghu Ram, India

14:00-14:15  Onco-anaesthesia: Is anaesthetic technique a risk factor for outcome?
              Bernhard Riedel, Australia

14:15-14:45  DEBATE: That percutaneous ablation is a useful treatment option in early breast cancer
              Yes: Dennis Holmes, USA
              No: Andrew Spillane, Australia

14:45-15:00  How should quality of life be assessed after breast cancer surgery
              Elisabeth Elder, Australia

15:00-16:15   Plenary Session 20: Breast Cancer 2025

Chairpersons: Christobel Saunders, Australia
              Yvonne Zissiadis, Australia

15:00-15:15  Breast cancer prevention in 2025
              Jack Cuzick, UK

15:15-15:30  A pathologist’s view of breast cancer in 2025
              Sunil R. Lakhani, Australia

15:30-15:45  How might immunotherapy be used in breast cancer?
              Sherene Loi, Australia

15:45-16:00  A radiation oncologist’s view of breast cancer in 2025
              Reshma Jagsi, USA

16:00-16:15  A surgeon’s view of breast cancer in 2025
              Laura Esserman, USA

16:15-16:30   Congress closing and Award presentation

Chairpersons: Christobel Saunders, Australia
              Yvonne Zissiadis, Australia
              Bruce Mann, Australia
**POSTER PRESENTATIONS**

**Friday, October 12, 2018**

**Adjuvant endocrine therapy**

**P01** ANTI-HORMONAL THERAPY ALONE IN N1 STAGE BREAST CANCER PATIENTS WITH HORMONE RECEPTOR POSITIVE AND HER-2 NEGATIVE  
*Sung-Ui Jung, South Korea*

**P02** MALE BREAST CANCER IN AUSTRALIA: COMPLIANCE WITH TREATMENT KEY PERFORMANCE INDICATORS – 99,768 BREAST CANCERS OVER A 10 YEAR PERIOD  
*Chris Lomma, Australia*

**P03** SYSTEMIC ADJUVANT TREATMENT RECOMMENDATIONS AND COMPLIANCE IN AUSTRALIAN PATIENTS WITH EARLY BREAST CANCER  
*Chris Lomma, Australia*

**Bone health**

**P04** PERCUTANEOUS PEDICLE SCREW FIXATION FOLLOWED BY CEMENTOPLASTY: A MINIMALLY INVASIVE TECHNIQUE FOR SPINAL METASTASIS IN BREAST CANCER PATIENTS  
*Claudio Pusceddu, Italy*

**Breast cancer genetics**

**P05** PREVALENCE OF OESTROGEN RECEPTOR POSITIVE BREAST CANCER IN OBESITY PATIENTS: A RETROSPECTIVE STUDY  
*Nur Aziah Binti Adib Anuar, Malaysia*

**P06** LVI IS IT MORE WORSE PREDICT OUTCOME THAN WE BELIEVE WE KNOW ABOUT IT? SYSTEMIC REVIEW OF SINGLE INSTITUTE IN SAUDI ARABIA  
*Abdulaziz Alhamad, Saudi Arabia*

**P07** METHYLATION STATUS OF MGMT AND MEG3 GENE’S PROMOTERS IN TRIPLE-NEGATIVE BREAST CANCER  
*Sylwia Sloniec, Poland*

**Breast imaging**

**P08** FEATURE OF THE BREAST LESION CAN BE DECEPTIVE: MIMICKERS OF BREAST MALIGNANCY  
*Visnja Baksa Reynolds, Singapore*

**P09** SHEAR WAVE ULTRASOUND AND HIGH MAMMOGRAPHIC BREAST DENSITY (HMBD); A PILOT STUDY OF BREAST STIFFNESS REDUCTION IN PRE-MENOPAUSAL WOMEN WITH HMBD  
*Stephen Birrell, Australia*

**P10** LITERATURE REVIEW AND CASE REPORT OF GRANULAR CELL TUMOUR IN BREAST  
*Amy Cao, Australia*

**P11** THE IMPACT OF PRE-OPERATIVE MRI IN THE MANAGEMENT OF INVASIVE LOBULAR CARCINOMA OF THE BREAST  
*Jennifer Chang, New Zealand*

**P12** KEEP CALM, IT’S JUST ‘MOOBS’  
*Mei Chan Chin, Australia*

**P13** THE BRILLIANCE OF CONTRAST ENHANCED SPECTRAL MAMMOGRAPHY (CESM)  
*Laurence Gluch, Australia*

**P14** COMPARISON OF USEFULNESS OF ULTRASOUND AND MRI FOR DIAGNOSIS OF SILICON BREAST IMPLANT RUPTURE  
*Naoya Gomi, Japan*
P15 FEATURES OF IMAGE FINDINGS OF DIGITAL BREAST TOMOSYNTHESIS (DBT) UNDETECTED BREAST CANCER
Mari Kikuchi, Japan

P16 APPROACHING BREAST IMPLANT ASSOCIATED COMPLICATION WITH ULTRASOUND AND CHECKLIST
Angela Soeun Lee, South Korea

P17 SQUAMOUS CELL METAPLASIA OF LACTIFEROUS DUCTS IN MALE PATIENTS
Rachael Manning, Australia

P18 WHICH IS THE BETTER METHOD TO DETECT ABNORMALITIES BY VISUAL ESTIMATE OR VOLPARA™ FOR WOMEN WITH DENSE BREAST?
Misaki Matsuyanagi, Japan

P19 FALSE NEGATIVE ON COMPUTER-AIDED DETECTION APPLICATION IN PREOPERATIVE AUTOMATED BREAST ULTRASOUND OF BREAST CANCER PATIENTS
Jiwon Rim, South Korea

P20 IMPACT OF PRE-OPERATIVE BREAST MRI ON BREAST CANCER TREATMENT PLANNING
Masuma Sarker, UK

P21 THE BREAST CANCER RELATED-RISKS IN WOMEN WITH DENSE BREAST TISSUE IS CLARIFIED BY USING VOLPARA™
Terumasa Sawada, Japan

P22 DIAGNOSTIC VALIDITY OF SURGEON-PERFORMED BREAST ULTRASOUND FOR FEMALES WITH PALPABLE BREAST MASSES
Apple Valparaiso, Philippines

P23 THE DIFFERENTIAL DIAGNOSIS OF THE BREAST FINDINGS USING AUTOMATED BREAST VOLUME SCANNER (ABVS) AND ADVANCED ELASTOGRAPHY
Mihaela Vancu, Romania

P24 INFLUENCE OF PRE-OPERATIVE BREAST CANCER LOCALIZATION TECHNIQUES ON RATES OF SENTINEL LYMPH NODE VISUALIZATION WITH PREOPERATIVE LYMPHOSCINTIGRAPHY
Shipra Verma, Australia

Breast reconstruction

P25 PREPECTORAL IMMEDIATE IMPLANT-BASED RECONSTRUCTION USING BRAXON: AN ACELLULAR DERMAL MATRIX – NATIONAL AUDIT FROM THE UNITED KINGDOM
Dayalan Clarke, UK

Endocrine resistance

P26 RIBOCICLIB + FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR+), HER2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): RESULTS FROM MONALEESA-3
Arlene Chan, Australia

P27 SINGLE CENTER STUDY IN THE PHILIPPINES ON ERIBULIN MESYLATE IN METASTATIC BREAST CANCER FROM 2013 - 2016
Amabelle Trina Gerona, Philippines

Molecular assays

P28 OPTIMA: A PROSPECTIVE RANDOMISED TRIAL TO VALIDATE THE CLINICAL UTILITY AND COST-EFFECTIVENESS OF GENE EXPRESSION TEST-GUIDED CHEMOTHERAPY DECISIONS IN HIGH CLINICAL RISK EARLY BREAST CANCER
Janet Dunn, UK

P29 TUMOR MICROENVIRONMENT AND ITS PHARMACOLOGICAL MODULATION IN A BREAST CANCER MODEL: PARALLELS TO SKIN WOUND HEALING
Peter Gal, Slovakia

P30 EXPLORING IN VITRO ANDROGEN BIOASSAYS AS A CLINICAL TOOL FOR BREAST CANCER
Rachel Lund, New Zealand
Neoadjuvant therapy

P31 PATHOLOGIC OUTCOMES OF HER2 POSITIVE NON METASTATIC BREAST CANCER PATIENTS TREATED WITH NEOADJUVANT DUAL ANTI HER2 THERAPY AND TAXANE AT SYDNEY ADVENTIST HOSPITAL (SAH)
Joseph Do Woong Choi, Australia

P32 DESIGN OF PERSIA: PERTUZUMAB STUDY FOR HER2-POSITIVE NON-METASTATIC BREAST CANCER IN THE NEOADJUVANT SETTING IN AUSTRALIA
Richard De Boer, Australia

P33 PREDICTIVE FACTORS OF STABLE OR PROGRESSIVE DISEASE DURING ANTHRACYCLINE WITH/WITHOUT TAXANE-BASED NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER
Ji Young Kim, South Korea

Prevention

P34 EARLY-LIFE BODY FATNESS IN RELATION TO TEXTURE VARIATION ON A MAMMOGRAM
Hannah Oh, South Korea

P35 COMPLIANCE WITH MULTIDISCIPLINARY TEAM MEETING TREATMENT RECOMMENDATIONS
Amali Samarasinghe, Australia

Radiotherapy

P36 DOES THE TUMOR BED SURGICAL CLIPS AFFECT DOSIMETRIC CHANGES IN THREE-DIMENSIONAL FIELD-IN-FIELD WHOLE-BREAST IRRADIATION TECHNIQUES FOR PATIENTS UNDERGOING BREAST CONSERVING SURGERY?
Dong Soo Lee, South Korea

Supportive care

P37 IMAGING-PROVEN VENOUS THROMBOEMBOLISM AMONG BREAST CANCER PATIENTS IN A TERTIARY HOSPITAL IN THE PHILIPPINES FROM 2010-2015
Amabelle Trina Gerona, Philippines

P38 THE EFFICACY OF BILASTINE FOR TAXANE REGIMENS INDUCED RASH
Taizo Hirata, Japan

P39 FEASIBILITY OF SEGMENTAL ECW/TBW RATIO FOR MILD TO MODERATE DEGREE BREAST CANCER-RELATED LYMPHEDEMA: CORRELATION WITH TAPE CIRCUMFERENTIAL VOLUME MEASUREMENT
Woo Gyeong Kim, South Korea

P40 CONSENT IN THE AGE OF WHITAKER AND MONTGOMERY: TIPTOEING THROUGH THE MINEFIELD OF PATIENT AUTONOMY
Mona Tan, Singapore

Survivorship

P41 LYMPHATIC MICRO SURGICAL PREVENTING HEALING APPROACH (LYMPHA): A SYSTEMATIC REVIEW
Natalia Garibotto, Australia

P42 PLEOMORPHIC LOBULAR BREAST CANCER: DOES MORPHOLOGY MATTER?
Laurence Gluch, Australia

P43 ETHNIC DISPARITIES IN THE INCIDENCE OF PHYLLODES TUMOURS AT COUNTIES MANUKAU HEALTH
Megan Grinlinton, New Zealand

P44 UTILITY OF SERUM TUMOUR MARKER VELOCITY OF CANCER ANTIGEN 15-3 (CA15-3) AND CARCINOEMBRYONIC ANTIGEN (CEA) IN BREAST CANCER SURVEILLANCE
Jun Xian Hing, Singapore

P45 TREATMENT PATTERNS AND CLINICAL OUTCOMES IN ELDERLY BREAST CANCER PATIENTS
Eunyoung Kang, South Korea
P46 IMPACT OF VITAMIN D ON BREAST CANCER OUTCOME
Trisha Khoo, Australia

P47 OLIGOMETASTATIC BREAST CANCER: CAN WE EVER SAY CURE?
Tahlia Molinaro, Australia

P48 QUALITY OF LIFE AND BODY IMAGE IN WOMEN WITH SURGERY FOR BREAST CANCER IN SINGAPORE
Siau Wei Tang, Singapore

P49 ESTABLISHING ROUTINE COLLECTION OF PATIENT-REPORTED OUTCOMES VIA THE BREASTSURGANZ QUALITY AUDIT: A PROOF-OF-PRINCIPLE PROJECT TO TEST FEASIBILITY
David Walters, Australia

P50 BREAST CANCER FOLLOW-UP: THE PATIENTS PERSPECTIVE
Maggie Wilcox, UK

P51 PHYSIOTHERAPY MANAGEMENT OF BREAST CANCER TREATMENT-RELATED FATIGUE, LYMPHOEDEMA, METASTATIC AND RADIATION-INDUCED BRACHIAL PLEXOPATHY: A CASE REPORT
Wai Yeung, Australia

P52 WALKING THE BOUNDARIES: IS THE 6-MINUTE WALK TEST ACHIEVABLE IN AN OUTPATIENT BREAST CLINIC?
Lei Ying, Australia

Triple negative breast cancer

P53 HEALTH CARE RESOURCE UTILIZATION FOR PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER (mTNBC) IN THE REAL WORLD CLINICAL SETTING: AN OBSERVATIONAL BREAST CANCER (OBTAIN) STUDY FROM AUSTRALIA
Elani Bowers, Australia

P54 THE MANAGEMENT OF BRCA PATIENTS IN THE WELLINGTON REGION: A 10 YEAR OVERVIEW
Sue Hui Ong, New Zealand

P55 RADIOGENOMIC ANALYSIS OF TRIPLE NEGATIVE BREAST CANCER: FEATURES OF RADIOMICS AND TRANSCRIPTOMICS
Sung Ui Shin, South Korea

Saturday, October 13, 2018

Breast cancer screening

P01 LOBULAR NEOPLASIA IN BREAST SCREEN SETTING MULTICENTRE STUDY (ST VINCENT AND MONASH) RETROSPECTIVE, DESCRIPTIVE STUDY: 23 YEARS (1993-2016)
Parisa Aminzadeh, Australia

P02 ZnR/GPR39 MODULATES KCC ACTIVITY IN ESTROGEN NEGATIVE BREAST CANCER CELLS
Moumita Chakraborty, Israel

P03 ROS-MEDIATED APOPTOSIS INDUCED BY FRUIT POLYPHENOLS IS FOLLOWED BY P38MAPK, ERK1/2 AND THE AKT SIGNALING PATHWAYS MODULATION IN BREAST CARCINOMA MODEL
Matus Coma, Slovakia

P04 IS ASYMPTOMATIC SURVEILLANCE AFTER STANDARD TREATMENT BENEFICIAL?: A 10 YR-SURVIVAL ANALYSIS OF RECURRENT BREAST CANCER PATIENTS BY DETECTION METHOD OF RECURRENCE
Han Shin Lee, South Korea

P05 OPTIMISING THE EARLY DETECTION OF BREAST CANCER IN AUSTRALIA
Carolyn Nickson, Australia

P06 USING THE GAIL MODEL TO RISK-STRATIFY WOMEN FOR BREAST CANCER SCREENING: MODEL VALIDATION ON 40,000 AUSTRALIAN WOMEN ATTENDING BREASTSCREEN
Carolyn Nickson, Australia
P07 SOME OPTIONS FOR COMBINING QUESTIONNAIRE AND MAMMOGRAPHIC DENSITY MEASURES TO ESTIMATE RISK OF FUTURE INVASIVE BREAST CANCER AND INTERVAL CANCERS IN SCREENED WOMEN
Carolyn Nickson, Australia

P08 MACHINE LEARNING MODELS FOR POPULATION-LEVEL RISK STRATIFICATION
Pietro Procopio, Australia

P09 RELIABILITY OF SUSPICION OF MALIGNANT BREAST MASS IN AUTOMATED BREAST ULTRASOUND (ABUS) EXAMINATION: AUTOMATED VERSUS HANDHELD BREAST ULTRASOUND
Jiwon Rim, South Korea

Breast reconstruction

P10 SCARLESS LATISSIMUS DORSI FLAP: AN EXCELLENT OPTION FOR LOWER POLE COVER IN IMPLANT BASED RECONSTRUCTION FOR A CHALLENGING SUBSET OF PATIENTS
Vanitha Budhavaram, Australia

P11 SINGLE PORT LAPAROSCOPIC HARVESTED OMENTAL FLAP FOR IMMEDIATE BREAST RECONSTRUCTION: EXPERIENCE IN SEOUL NATIONAL UNIVERSITY BUNDANG HOSPITAL
Sumin Chae, South Korea

P12 DOES IMMEDIATE BREAST RECONSTRUCTION LEAD TO A DELAY IN ADJUVANT CHEMOTHERAPY FOR BREAST CANCER?: A META-ANALYSIS AND SYSTEMATIC REVIEW
Patrick Cook, Australia

P13 BREAST RECONSTRUCTION IN THE REGIONAL SETTING: 5 YEARS OF EXPERIENCE
Daniel Keating, Australia

P14 CLINICAL AUDIT REDUCTION MAMMOPLASTY FROM 2011 TO 2016: AN ASSESSMENT OF SURGICAL OUTCOME AND WAITING PERIOD IN A TERTIARY PUBLIC HOSPITAL
Jeffrey Smith, Australia

DCIS

P15 ACTIVE MONITORING VERSUS IMMEDIATE TREATMENT FOR WOMEN WITH LOCALISED, LOW-RISK DUCTAL CARCINOMA IN SITU: DOES IT MAKE ECONOMIC SENSE?
Hannah Bromley, Australia

P16 TRIPLE NEGATIVE DCIS
Sayuka Nakayama, Japan

Local therapy

P17 RADIO-GUIDED OCCULT LESION LOCALISATION USING IODINE-125 SEEDS (ROLLIS) IS A SAFE ALTERNATIVE TO HOOK-WIRE LOCALISATION (HWL)
Brenno Becker, Australia

P18 THE USE OF WIRELESS TECHNOLOGY IN BREAST CANCER: HOW TO START YOUR OWN RADIOGUIDED OCCULT LESION LOCALISATION PROGRAMME USING IODINE – 125 SEEDS (ROLLIS)
Brenno Becker, Australia

P19 CLINICOPATHOLOGIC PROFILE AND OUTCOMES OF PHYLLODES TUMOR OF THE BREAST: A 10-YEAR REVIEW OF A PHILIPPINE TERTIARY HOSPITAL EXPERIENCE
Shiela Macalindong, Philippines

P20 CAN METHYLENE BLUE DYE BE USED AS AN ALTERNATIVE TO PATENT BLUE DYE TO FIND THE SENTINEL LYMPH NODE IN BREAST CANCER SURGERY?
Omid Rouhbakhshfar, Iran

P21 MUCINOUS BREAST CARCINOMA. A SINGLE INSTITUTION EXPERIENCE
Nikolaos Salemis, Greece

P22 OPTIMAL TREATMENT MODALITY OF PSEUDOANGIOMATOUS STROMAL HYPERPLASIA OF THE BREAST
Kwanghyun Yoon, South Korea
Locoregional therapy

P23  LITERATURE REVIEW AND THREE CASE REPORTS OF BREAST FIBROMATOSIS: A MASQUERADE OF BREAST CANCER
Amy Cao, Australia

P24  A NOVEL PREDICTIVE TOOL FOR HEAVY AXILLARY NODAL INVOLVEMENT IN SENTINEL NODE POSITIVE BREAST CANCER
Nipu Jayatilleke, Australia

P25  MAGNETIC TRACER USE FOR SENTINEL NODE BIOPSY: INTRODUCTION TO AN AUSTRALASIAN PILOT STUDY
Ahrin Anna Morrow, New Zealand

P26  IMPACT OF THE AMERICAN COLLEGE OF SURGEONS ONCOLOGY GROUP Z0011 TRIAL ON THE MANAGEMENT OF POSITIVE AXILLARY NODES IN THE AUSTRALIAN SETTING
Nicholas K. Ngui, Australia

P27  OUTCOMES OF RIB RESECTION FOR BREAST TUMORS EXTENDING TO THE CHEST WALL
Kristine Paguirigan, Philippines

P28  DISCUSSION ON INDICATIONS OF INTERNAL MAMMARY SENTINEL LYMPH NODE BIOPSY IN BREAST CANCER IN THE ERA OF PRECISION MEDICINE
Peng-Fei Qiu, China

P29  A PROSPECTIVE COMPARATIVE DOUBLE ARM STUDY OF SLNB WITH ICG BASED TECHNIQUE VERSUS COMBINATION DUAL DYE TECHNIQUE FOR EARLY BREAST CANCER: FIRST INDIAN STUDY
S.P. Somashekhar, India

P30  THE ‘TWINKLE’ ARTEFACT: A NOVEL METHOD OF CLIP IDENTIFICATION TO FACILITATE TARGETED AXILLARY SURGERY FOLLOWING NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS
Mona Tan, Singapore

P31  INDOCYANINE GREEN FLUORESCENCE VERSUS BLUE DYE OR RADIOISOTOPE FOR DETECTION RATE OF SENTINEL LYMPH NODE BIOPSY AND NODES REMOVED IN BREAST CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
Sarun Thongvitokomarn, Thailand

P32  BREAST CANCER ANATOMIC STAGING WITH RISK SCORE IS SIMPLE TO USE AND EFFECTIVE
Ru Xin Wong, Singapore

Oncoplastic surgery

P33  PERFORATOR FLAPS FOR BREAST CONSERVING SURGERY: RESULTS FROM AN EARLY SERIES
Nita Bartlett, Australia

P34  IMAGING RESULTS FOLLOWING PARTIAL BREAST RECONSTRUCTION WITH CHEST WALL PERFORATOR FLAPS: A QUALITATIVE ANALYSIS WHEN COMPARED TO STANDARD BREAST CONSERVING SURGERY
Jesse Hu, Singapore

P35  PREOPERATIVE 3D PRINTING TO AID PLANNING IN COMPLEX BREAST PROCEDURES
Raiiya Mousina, Australia

P36  DOES ONCOPLASTIC SURGERY HAVE A ROLE IN OPTIMISING BREAST CONSERVATION TREATMENT IN AN ASIAN CONTEXT?
Mona Tan, Singapore

P37  EFFICACY AND SAFETY OF TRANEXAMIC ACID IN ONCOPLASTIC BREAST SURGERY: A SYSTEMATIC LITERATURE REVIEW
Kartik Vasan, Australia

P38  PRACTICE PATTERNS OF ANTIBIOTIC PROPHYLAXIS IN ONCOPLASTIC BREAST SURGERY: A NATIONWIDE AUSTRALIAN SURVEY
Kartik Vasan, Australia
Radiotherapy

P39 ACCELERATED PARTIAL BREAST IRRADIATION (APBI) WITH EXTRACRANIAL STEREOTACTIC RADIOThERAPY (SBRT) AND EXACTRAC ADAPTIVE GATING IN LOW-RISK EARLY BREAST CANCER: 5-YEAR FOLLOW-UP
Angel Acosta Rojas, Spain

P40 POST-MASTECTOMY HYPOFRACTIONATED LOCOREGIONAL IRRADIATION (HLRI)
Angel Acosta Rojas, Spain

P41 HYPOFRACTIONATED RADIOThERAPY IN LOCALLY ADVANCED BREAST CANCER AFTER CONSERVATIVE SURGERY
Angel Acosta Rojas, Spain

P42 HYPOFRACTIONATED ACCELERATED RADIOThERAPY FOR DUCTAL CARCINOMA IN SITU (DCIS)
Angel Acosta Rojas, Spain

P43 INTRAOPERATIVE RADIOThERAPY FOR EARLY STAGE BREAST CANCER AT THE MONASH CANCER CENTRE: FEASIBILITY AND ACUTE TOXICITY
Steven David, Australia

P44 DEVELOPMENT OF A TREATMENT TECHNIQUE FOR THE AEROFORM™ TISSUE EXPANDER BREAST IMPLANT SYSTEM: A SINGLE DEPARTMENT EXPERIENCE
Jennie Gilliman, Australia

P45 EVALUATION OF SETUP ACCURACY FOR PRONE BREAST RADIOThERAPY WITH A 3D SURFACE IMAGING SYSTEM
Sunmi Jo, South Korea

P46 DEEP INSPIRATION BREATH HOLD COMPLIANCE RATE AT SIMULATION AT GENESISCARE VICTORIA
Cynleen Kai, Australia

P47 COMPARING EVIDENCE-BASED RECOMMENDATIONS FOR RADIOThERAPY USE AGAINST ROUTINE PRACTICE IN BREAST CANCER
Roya Merie, Australia

P48 UTILITY OF DEEP INSPIRATORY BREATH HOLD (DIBH) IN THE RADIOThERAPEUTIC MANAGEMENT OF RIGHT SIDED BREAST CANCER
Andrew See, Australia

P49 PARADIGMS IN BREAST CANCER MANAGEMENT IN PREVIOUSLY AUGMENTED BREASTS: TIME FOR A CHANGE?
Kartik Vasan, Australia

Molecular Assays

P50 NETRIN-1 EXPRESSION IN BREAST CANCER
Shyr-Ming Sheen-Chen, Taiwan
INDUSTRY

Melbourne International Joint Breast Congress

Australasian Society for Breast Disease (ASBD)

4th World Congress on Controversies in Breast Cancer (CoBrCa)

Breast Surgeons of Australia & New Zealand (BreastSurgANZ)
The MIBC Congress would like to thank the supporters. It is with the support of the industry that MIBC can continue in its mission to promote research and education and to disseminate new knowledge.
LIST OF EXHIBITORS
Industry Symposia

Friday, October 12, 2018

07:00-08:30  Morning Industry Symposium:  
Practice-changing new perspectives on genomic profiling in the management of  
HR+, HER2- Early Breast Cancer  
Supported by Genomic Health

Chairpersons:  
Bruce Mann, Australia  
Elgene Lim, Australia

07:15-07:20  Introduction  
Elgene Lim, Australia

07:20-07:50  Level 1 Evidence on the Oncotype DX Breast Recurrence Score® Assay and  
Implications for Clinical Practice  
Virginia Kaklamani, USA

07:50-08:25  Panel Discussion/Case Studies

Chairs:  
Bruce Mann, Australia  
Elgene Lim, Australia

Panelists:  
Virginia Kaklamani, USA  
Richard de Boer, Australia  
Cindy Mak, Australia

07:00-08:30  Morning Industry Symposium:  
CDK4/6 inhibitors in advanced breast cancer: The future is now  
Supported by Pfizer

Chairpersons:  
Arlene Chan, Australia  
Catherine Oakman, Australia

07:15-07:45  The science behind CDK4/6 inhibition  
Javier Cortes, Spain

07:45-08:15  DEBATE: That all 1st line stage 4 ER+/HER2-patients should have a CDK4/6 inhibitor  
Yes: Rebecca Dent, Singapore  
No: Nick Murray, Australia

08:15-08:30  Discussion
11:30-12:30  Industry Symposium:
Clinical controversies in HER2+ early breast cancer
Supported by Roche

Chairpersons:  Fran Boyle, Australia
                Catherine Shannon, Australia

11:30-11:45  Neo-adjuvant therapy in HER2 positive disease
Javier Cortes, Spain

11:45-12:15  DEBATE: That all high-risk adjuvant HER2 patients should receive dual antibody therapy
11:45  Yes:  Javier Cortes, Spain
11:55  No:  Nicholas Wilcken, Australia
12:05  Discussion

12:15-12:30  Case studies: HER2 +ve neo-adjuvant and adjuvant setting
Moderator:  Fran Boyle, Australia
            Javier Cortes, Spain
            Richard de Boer, Australia
            Nicholas Wilcken, Australia

13:30-14:30  Industry Symposium:
New paradigms in the treatment of HR+HER2- mBC: CDK4/6 inhibitors and beyond
Supported by Novartis

Chairpersons:  Richard de Boer, Australia
                Belinda Yeo, Australia

13:30-13:35  Welcome
Richard de Boer, Australia
Belinda Yeo, Australia

13:35-13:55  Role of CDK4/6 Inhibitors in overcoming endocrine resistance: Are they all the same?
Stephen Johnston, UK

13:55-14:10  CDK4/6 Inhibitors: The Australian experience, and what to do after progression?
Elgene Lim, Australia

14:10-14:30  Case studies and panel discussion
Saturday, October 13, 2018

07:00-08:30 Morning Industry Symposium: 
Old favourites, new strategies: Chemotherapy and the treatment of MBC 
Supported by Eisai

Breakfast will be served prior to the session

Chairpersons: Nicole McCarthy, Australia
Chris Hart, Australia

07:15-07:45 How can we partner chemotherapy with immunotherapy? 
Javier Cortes, Spain

07:45-08:15 In the era of CDK inhibition and targeted agents for MBC, does chemotherapy still have a place? 
Linda Vahdat, USA

08:15-08:30 Discussion

07:00-08:30 Morning Industry Symposium: 
Attractive techniques for localisation and staging: Tools for everyone 
Supported by EBOS and Magseed

Breakfast will be served prior to the session

Chairperson: Bruce Mann, Australia

07:15-07:35 Magtrace for sentinel node localisation 
Alastair Thompson, USA

07:35-08:00 Targeted Axillary Dissection with Magseed 
Abigail Caudle, USA

08:00-08:25 Discussion

11:30-13:00 Industry Symposium: 
Key issues around bone health 
Supported by Amgen

Chairperson: Nicholas Wilcken, Australia

11:30-12:00 DEBATE: That a bone targeted agent should be routine for post-menopausal HR+ve patients
11:30 Yes: Arlene Chan, Australia
11:40 No: Catherine Shannon, Australia
11:50 Discussion

12:00-12:20 Bone agents for stage 4 disease: How long, for how often and at what cost? 
Richard de Boer, Australia

12:20-12:40 The mythology of Vitamin D in disease 
Ego Seeman, Australia

12:40-13:00 Discussion
# Floor Plan

## Show Details
- **Show Date:** 11 - 14TH OCTOBER 2018
- **Venue:** MIBCM18
- **Location:** BAY 21 & 22 (NEW EXPANSION AREA)

## Specifications
- **33 x (3x2M) Syma Booths**
- **1 x (4x3M) Syma Booths**
- **2 x (6x3M) Syma Booths**
- **30 x (1.2m) D/S Poster Boards**

This plan is subject to change, venue approval & a site inspection once sign off has been accepted.

## Exhibitors
1. Bio-Strategy
2. Melbourne Pathology / Sonic Genetics
3. alpha XRT
4. Bard
5. BCNA
6. Defries
7. Martix Surgical
8 & 9. Zeiss
10. Myriad
11. Specialized Therapeutics
12. Eisai
13. Surgical Supplies Aus.
14. Medilink Australia
15. Surgeons Choice
16. Spiran
17. Aspen Australia
18. Hologic
19. Aurora BioScience
20. GEHealthcare
21. Lilly Barista Cart
22. Smith and Nephew
23. GRC Surgical
24. Amgen
25. Novartis
26. LifeHealthcare
27. ICON Group
28. J&J
29. Medical Specialties Australasia
30. Roche
31. Volpara Solutions
32. Endotherapeutics
33. Integra
34. Pfizer
35. Regional Healthcare
36. Device Technologies
37. ANSTO
38. EBOS/Magseed